Bevacizumab therapy for POEMS syndrome [7]

Blood

Volumn 107, Issue 12, 2006, Pages 4973-4974

  Badros, Ashraf Z ^a   Jaccard, Arnaud ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; VASCULOTROPIN;

ADULT; ARTIFICIAL VENTILATION; BLEEDING; CASE REPORT; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; LABORATORY TEST; LETTER; PARAPROTEINEMIA; PRIORITY JOURNAL;

EID: 33745075300     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Hashiguchi T, Arimura K, Matsumuro K, et al. Highly concentrated vascular endothelial growth factor in platelets in Crow-Fukase syndrome. Muscle Nerve. 2000;23:1051-1056.
2. Kuwabara S, Misawa S, Kanai K, et al. Autologous peripheral blood stem cell transplantation for POEMS syndrome. Neurology. 2006;66:105-107.
3. Scarlato M, Previtali SC, Carpo M, et al. Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. Brain. 2005;128:1911-1920.
4. Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature. 2005;437:497-504.
5. Koga H, Tokunaga Y, Hisamoto T, et al. Ratio of serum vascular endothelial growth factor to platelet count correlates with disease activity in a patient with POEMS syndrome. Eur J Intern Med. 2002;13:70-74.